Share on StockTwits

Aldeyra Therapeutics (NASDAQ:ALDX) Director C. Boyd Clarke purchased 3,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average cost of $3.69 per share, for a total transaction of $11,070.00. Following the acquisition, the director now directly owns 15,500 shares in the company, valued at approximately $57,195. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Separately, analysts at Aegis initiated coverage on shares of Aldeyra Therapeutics in a research note on Thursday, June 19th. They set a “buy” rating and a $35.00 price target on the stock.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at 4.1499 on Friday. Aldeyra Therapeutics has a one year low of $3.00 and a one year high of $8.222. The stock has a 50-day moving average of $5.32 and a 200-day moving average of $6.00. The company’s market cap is $25.9 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.56) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.53) by $1.03. Analysts expect that Aldeyra Therapeutics will post $-1.49 EPS for the current fiscal year.

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) is a biotechnology company.

Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.